4.3 Review

Pluripotency inducing Yamanaka factors: role in stemness and chemoresistance of liver cancer

Journal

EXPERT REVIEW OF ANTICANCER THERAPY
Volume 21, Issue 8, Pages 853-864

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/14737140.2021.1915137

Keywords

Yamanaka factors; stemness; chemoresistance; liver cancer

Categories

Funding

  1. University Grants Commission [F.30-377/2017(BSR)]
  2. DST-SERB, India [EMR/20l7/001758]

Ask authors/readers for more resources

OSKM factors play a crucial role in inducing pluripotency and stem cell-like properties, particularly in liver cancer. Their deregulation in CSCs leads to stemness and drug resistance, highlighting the importance of understanding their role in cancer stemness and chemoresistance.
Introduction: Liver cancer is a major cause of mortality and is characterized by the transformation of cells into an uncontrolled mass of tumor cells with many genetic and epigenetic changes, which lead to the development of tumors. A small subpopulation of cell population known as Cancer Stem Cells (CSCs) is responsible for cancer stemness and chemoresistance. Yamanaka factors [octamer-binding transcription factor 4 (OCT4), SRY (sex-determining region Y)-box 2 (SOX2), kruppel-like factor 4 (KLF4), and Myelocytomatosis (MYC); OSKM] are responsible for cancer cell stemness, chemoresistance, and recurrence. Area covered: We cover recent discoveries and investigate the role of OSKM in inducing pluripotency and stem cell-like properties in various cancers with special emphasis on liver cancer. We review Yamanaka factors' role in stemness and chemoresistance of liver cancer. Expert opinion: In CSCs, including liver CSCs, the deregulation of various signaling pathways is one of the major reasons for stemness and drug resistance and is primarily due to OSKM. OSKM are responsible for tumor heterogeneity which renders targeting drug useless after a certain period. These factors can be exploited to understand the underlying mechanism of cancer stemness and resistance to chemotherapeutic drugs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available